跳至主要内容
临床试验/JPRN-UMIN000012668
JPRN-UMIN000012668已完成未知

Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure - Simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure

Osaka University Graduate school of Medicine0 个研究点目标入组 45 人开始时间: 2013年12月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients with co-infection with hepatitis B virus or human immunodeficiency virus or alcoholic liver disorder or autoimmune hepatitis. 2) Patients with uncompensated cirrhosis or hepatic failure 3) Patients with multiple organ failure or immunological deficiency 4) Patients with severe depression or past history of psychiatric disorder 5) Patients in pregnancy or lactating or patients who expect to become pregnant

研究者

相似试验